By combining three powerful mechanisms in one therapy, it demonstrates how multi-receptor peptides can deliver broader, more durable results than ever before
Food and Drug Administration how it will prevent unvetted shipments of the active pharmaceutical ingredients (API) in injectable weight loss drugs like Ozempic from entering the country
Cardiovascular Outcomes# EXSCEL Trial (Exenatide)# The EXSCEL trial (Holman et al., NEJM 2017) enrolled 14,752 patients with type 2 diabetes (73.1% with prior cardiovascular disease) and followed them for a median of 3.2 years: Primary MACE endpoint : HR 0.91 (95% CI 0.83-1.00), p=0.06 for superiority Met non-inferiority but narrowly missed superiority (p=0.06) All-cause mortality was reduced by 14% (HR 0.86, p=0.016) in a secondary analysis EXSCEL confirmed cardiovascular safety but did not prove cardiovascular benefit -- a critical distinction
In recent years, certain GLP-1 treatments have been approved by the FDA for chronic weight management
Powder offers higher, flexible dosing, but it is bitter and easy to skip
The 0.5 mL syringe holds 50 units and works well for moderate volumes